Latest news with #Vyndaqel
Yahoo
05-06-2025
- Business
- Yahoo
Pfizer (NYSE:PFE) Exceeds Sales Milestone With Cresemba In Asia Pacific And China
Pfizer announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, marking significant growth in key Asian markets. Despite this achievement, Pfizer's stock price was relatively flat last week, reflecting a broader market trend rather than significant movements unique to the company. The company's announcements, including significant clinical trial results and strategic drug market expansions, provided positive context. However, these events primarily added weight to the overall market's modest rise, suggesting a stable, yet unremarkable impact on Pfizer's share price amid ongoing economic and trade developments. Be aware that Pfizer is showing 3 risks in our investment analysis. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Pfizer's recent announcement concerning Cresemba's sales growth in Asian markets is a positive indicator for its revenue outlook. However, despite these gains, Pfizer's shares have remained flat, reflecting broader market trends rather than company-specific news. This lack of movement underscores persistent challenges, such as competition and declining utilization of key drugs like Paxlovid and Vyndaqel, potentially impacting future revenues and earnings forecasts. Over the past five years, Pfizer's total shareholder return, including dividends, was a decrease of 13.55%. This decline highlights performance concerns, particularly as Pfizer underperformed the broader US market, which recorded an 11.6% gain over the last year. Despite becoming profitable this year, Pfizer's forecasted revenue contraction of 2.1% per year over the next three years reflects ongoing challenges within the pharmaceutical industry. Pfizer's current share price at approximately US$24.41 shows a sizable discount compared to the consensus analyst price target of US$29.24. This gap suggests moderate investor skepticism about future growth, as analysts expect profit margins to rise yet predict revenue and earnings pressures. While Pfizer aims to stabilize through R&D advancements and international market penetration, these efforts will need to counteract competition's influence to align closer with the anticipated price target. Unlock comprehensive insights into our analysis of Pfizer stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Globe and Mail
30-04-2025
- Business
- Globe and Mail
PFE Earnings: Pfizer Tops Q1 Profit Estimates Despite Lower Sales
Pfizer (PFE) delivered stronger-than-expected earnings for Q1 2025, posting an adjusted diluted EPS of $0.92, significantly above analysts' expectations of $0.60. The earnings beat was driven by effective cost-cutting measures and solid sales of its heart medication, Vyndaqel. However, the company missed revenue expectations due to declining COVID-related sales. Pfizer reported first-quarter revenue of $13.70 billion, falling short of the projected $13.97 billion. This also marked a year-over-year decline of 8%. PFE stock gained 0.69% in pre-market trading. Protect Your Portfolio Against Market Uncertainty Pfizer Sticks to 2025 Forecast, but Tariff Threat Looms Pfizer left its full-year 2025 guidance unchanged, expecting revenue between $61 billion and $64 billion. However, the company noted that this forecast does not account for any future impacts from tariffs or shifts in trade policy, which remain unpredictable. Pfizer, along with other drugmakers, faces potential challenges from proposed U.S. tariffs on pharmaceutical imports from countries like China, which is a key supplier of raw materials and medical products. Additionally, the company expects a $1 billion decline in 2025 sales due to changes in the Medicare program under the Inflation Reduction Act, which could slow overall growth by approximately 1.6% compared to 2024. Despite this expected headwind, the company remains focused on strengthening its financials. By the end of 2025, Pfizer aims to improve its operating margin through a cost-cutting initiative targeting roughly $4.5 billion in savings. Is Pfizer Stock a Good Buy Right Now? According to TipRanks, Wall Street has a Moderate Buy consensus rating on PFE stock, based on 12 Holds and six Buys assigned in the last three months. The average Pfizer stock price target of $27.75 implies over 20% upside potential. See more PFE analyst ratings
Yahoo
30-04-2025
- Business
- Yahoo
Pfizer Inc (PFE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline and Strategic Growth
Revenue: $13.7 billion, a decline of 6% operationally. Diluted EPS: $0.52 per share. Adjusted Diluted EPS: $0.92 per share. Adjusted Gross Margin: Approximately 81%. Total Adjusted Operating Expenses: $5.2 billion, a 12% decline operationally. Adjusted SI&A Expenses: Decreased 12% operationally. Adjusted R&D Expenses: Decreased 12% operationally. Dividend Returned to Shareholders: $2.4 billion. Internal R&D Investment: $2.2 billion. Full-Year 2025 Revenue Guidance: $61.0 to $64.0 billion. Full-Year 2025 Adjusted Diluted EPS Guidance: $2.80 to $3.00. Warning! GuruFocus has detected 6 Warning Signs with PFE. Release Date: April 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Pfizer Inc (NYSE:PFE) reported strong financial performance in Q1 2025, with a focus on improving operating margins and cash flow. The company is advancing its R&D pipeline with multiple anticipated milestones, including regulatory decisions and Phase 3 readouts. Pfizer Inc (NYSE:PFE) is expanding its commercial portfolio, with significant growth in key products like Vyndaqel, Nurtec, and Padcev. The company is committed to maintaining and growing its dividend, reinforcing its capital allocation strategy. Pfizer Inc (NYSE:PFE) is leveraging digital tools and automation to achieve significant cost savings, aiming for $7.7 billion in savings by 2027. Pfizer Inc (NYSE:PFE) experienced a 6% operational revenue decline in Q1 2025, largely due to lower Paxlovid revenues and changes in Medicare Part D design. The company faces challenges from competition in the market, particularly impacting the Vyndaqel family of products. There is uncertainty regarding potential tariffs, which could impact Pfizer Inc (NYSE:PFE)'s financial performance and manufacturing strategy. The discontinuation of the danuglipron program in the obesity portfolio highlights challenges in R&D prioritization. Pfizer Inc (NYSE:PFE) is navigating a complex global landscape with evolving trade and tariff policies, which could affect future operations. Q: Can you reinforce your commitment to maintaining and growing the dividend, especially with tariff uncertainties and potential impacts on cash flows? A: David Denton, CFO, emphasized that the dividend remains a critical component of Pfizer's capital allocation strategy. The company is focused on improving operating margins and cash flow yield to support all capital allocation priorities, including the dividend. Q: What are your expectations for the COVID business this year, considering the nuances around Paxlovid and vaccine sales? A: Aamir Malik, Chief US Commercial Officer, explained that Paxlovid utilization trends closely follow infection rates, with a 50% treatment rate and 80% fulfillment rate. The company expects multiple COVID waves this year and has set up a model to transition Medicare patients to a traditional model. Alexandre De Germay, Chief International Commercial Officer, added that Comirnaty performed well internationally, and Pfizer is preparing for vaccination campaigns in the Southern Hemisphere. Q: What are the key aspects you are looking for in a potential obesity asset, following the discontinuation of danuglipron? A: Chris Boshoff, Chief Scientific Officer, stated that Pfizer remains committed to obesity and is advancing its pipeline of differentiated oral medicines, including a GIPR antagonist in Phase 2. The focus is on tolerability, accessibility, and convenience, with an emphasis on personalized combinations addressing specific diseases associated with obesity. Q: How is Pfizer engaging with the 232 investigation on tariffs, and what is your best sense of timing for more information from the Administration? A: Albert Bourla, CEO, explained that the 232 investigation is focused on national security concerns related to the pharmaceutical supply chain. Pfizer is engaging with the Administration and is cautiously optimistic about the outcome. The investigation is expected to be completed within 270 days, but the Administration may work faster. Q: Can you provide more details on Pfizer's cost realignment program and its impact on 2025? A: David Denton, CFO, mentioned that Pfizer is on track to achieve $4.5 billion in savings by the end of 2025, with an additional $1.2 billion in savings expected by 2027. The focus is on improving productivity and operational efficiency, with some savings realized in 2025 and more in the following years. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
29-04-2025
- Business
- Yahoo
Pfizer profits dip on lower Paxlovid sales
Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects. Sales of Paxlovid slid 75 percent amid lower Covid-19 infections and reduced government purchases of the medication. But Pfizer scored higher revenues for its Covid-19 vaccine, along with some other products, including the heart medication Vyndaqel and the cancer drug Padcev. Profits in the first quarter fell five percent to $3.0 billion, while revenues dropped eight percent to $13.7 billion. Pfizer Chief Executive Albert Bourla said the company's discontinuation earlier this month of the Danuglipron obesity drug was the right call after a participant in a trial experienced a liver injury that cleared up after the treatment was stopped. Pfizer is developing other medications in the obesity and related areas and could pursue "external opportunities" such as partnerships or acquisitions, Bourla said. Pfizer is also working on treatments for a number of other ailments, including bladder cancer and multiple myeloma, Bourla said. "We are on track for a strong year of anticipated pipeline catalysts," he said. The drugmaker maintained its full-year sales forecast of between $61-64 billion. In 2024, Pfizer's revenues were $63.6 billion. The projection "does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time," Pfizer said. Pfizer said it is on track to deliver $4.5 billion in cost savings through the end of 2025. It also is implementing a reorganization of its research and development, and a manufacturing "optimization" program. Shares rose 0.5 percent in pre-market trading. jmb/aha Sign in to access your portfolio
RTÉ News
29-04-2025
- Business
- RTÉ News
Pfizer misses revenue expectations, sees $1.7 billion more in cost savings
Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations and reported lower first-quarter revenue due to declining sales of its Paxlovid Covid-19 treatment. The company reaffirmed its full-year forecast and announced measures to mitigate the impact of potential tariffs on pharmaceuticals by the Trump administration, including possibly shifting some production to the US. While the rates and timing of tariffs on the pharma sector are unclear, analysts expect that companies will have to absorb any near-term costs if they are imposed. Washington has launched an investigation into the industry, laying the groundwork for possible levies. Pfizer had an Irish workforce of about 5,000 across four locations based in Cork, Dublin and Kildare. Last month, Pfizer CEO Albert Bourla said the company has the capability to move overseas manufacturing to its existing US plants "if something happens." Pfizer has 10 manufacturing sites and two distribution centers in the US, employing nearly 10,000 people. "While we continue to engage and plan for contingencies, we're focusing day-to-day on what we can do to move our business forward," Bourla said in prepared remarks today. Potential tariffs could add to existing pressure for Pfizer. Investors have been pushing the company to bring new drugs to market that could make up for potential revenue lost from some top-selling medicines nearing the end of patent protection. Even the drugs that outperformed Wall Street expectations this quarter face headwinds. Sales of its heart disease drug, sold under the brand names Vyndaqel and Vyndamax, were $1.49 billion, above estimates of $1.29 billion. But the company said it is already seeing the impact of new competition, which it expects to continue through the year. Pfizer's vaccine business could also face greater regulatory scrutiny under the new Health Secretary Robert F Kennedy Jr, a longtime vaccine skeptic. Covid vaccine Comirnaty, which Pfizer makes with German partner BioNTech, brought in sales of $565m. Analysts were expecting sales of $331.7m for the shot. But sales of Covid antiviral Paxlovid were $491m, well short of analysts' already diminished expectations of $794.3m, according to LSEG data. Analysts had significantly cut their expectations for the two-drug treatment in recent weeks due to a relatively small winter wave of Covid-19 in the US. The company provided an update on its cost-cutting programmes, saying it now expects about $7.7 billion in savings by the end of 2027. On an adjusted basis, Pfizer earned 92 cents per share in the first quarter, compared with analysts' expectations of 66 cents per share, helped by cost cuts and a lower tax rate. Despite the earnings beat, Pfizer is still forecasting a full-year adjusted profit of $2.80 to $3 per share on revenue of $61 billion to $64 billion .
